Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


This Was Not a Budget for an Aspiration Nation

21 March 2013

Budget day provided an opportunity for the Chancellor to lay out a visionary, comprehensive and, above all, ambitious plan to restore the British economy to health. Sadly we didn't get it, says Professor Stephen Caddick (UCL Enterprise).

Read the full article at www.huffingtonpost.co.uk